Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1810109
Prognostic Significance of Serum-Soluble Endoglin (CD105) Levels in Patients with Acute Myeloid Leukemia
Funding and Sponsorship This work was supported by the Department of Scientific Research Projects (BAP) of Ataturk University (Grant number: TTU-2023-11939).
Abstract
Objective
We investigated the serum-soluble endoglin (CD105) levels and their prognostic significance in patients with acute myeloid leukemia (AML), given that angiogenesis, stimulated by vascular endothelial cells, is known to increase during AML development, and serum-soluble endoglin is a transmembrane protein that induces the activation and proliferation of these cells.
Materials and Methods
The study included 30 newly diagnosed or relapsed AML patients followed at the Hematology Clinic of Atatürk University Faculty of Medicine Hospital and 30 healthy individuals. The demographic characteristics, hemogram and biochemical parameters, performance scores, flow cytometry results, cytogenetic and molecular laboratory findings, follow-up durations, survival statuses, chemotherapy protocols, and patients' responses to chemotherapy were recorded. Serum-soluble endoglin was measured before and after chemotherapy in AML patients.
Results
Serum-soluble endoglin levels in AML patients before and after treatment were not significantly different (p = 0.494). The pretreatment serum-soluble endoglin (CD105) levels in AML patients were similar to those of the control group (p = 0.264). Endoglin (CD105) levels in the group that achieved remission after induction therapy and the refractory group were not significantly different (p = 0.245). Serum-soluble endoglin (CD105) levels were also similar between surviving patients and those who died (p = 0.07).
Conclusion
Serum-soluble endoglin (CD105) levels may not hold diagnostic or prognostic significance in AML patients.
Compliance with Ethical Principles
The Atatürk University Faculty of Medicine Clinical Research Ethics Committee approved this study (Date: 02.06.2022, Decision no: 34).
Authors' Contributions
All authors contributed to collecting the data, writing the article, reviewing, and approving the final article.
Publication History
Article published online:
22 July 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31 (Pt 2): 2349-2370
- 2 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (07) 1703-1719
- 3 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
- 4 Döhner H, Estey E, Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129 (04) 424-447
- 5 Lindsley RC, Mar BG, Mazzola E. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125 (09) 1367-1376
- 6 Olesen LH, Aggerholm A, Andersen BL. et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005; 131 (04) 457-467
- 7 Sekeres MA, Peterson B, Dodge RK. et al; Cancer and Leukemia Group B. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004; 103 (11) 4036-4042
- 8 Timilshina N, Breunis H, Brandwein JM. et al. Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?. Ann Oncol 2014; 25 (04) 883-888
- 9 Döhner H, Wei AH, Appelbaum FR. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 (12) 1345-1377
- 10 Schlenk RF, Döhner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009; 16 (02) 98-104
- 11 Kauer J, Schwartz K, Tandler C. et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep 2019; 9 (01) 18337
- 12 Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274 (02) 584-594
- 13 Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 2006; 56 (12) 717-723
- 14 Burrows FJ, Derbyshire EJ, Tazzari PL. et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1 (12) 1623-1634
- 15 Placencio-Hickok VR, Madhav A, Kim S. et al. Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. Endocr Relat Cancer 2020; 27 (01) 1-9
- 16 Chakhachiro ZI, Zuo Z, Aladily TN. et al. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol 2013; 140 (03) 370-378
- 17 Giorello MB, Martinez LM, Borzone FR. et al. CD105 expression in cancer-associated fibroblasts: a biomarker for bone metastasis in early invasive ductal breast cancer patients. Front Cell Dev Biol 2023; 11: 1250869
- 18 Mohamed SY, Mohammed HL, Ibrahim HM, Mohamed EM, Salah M. Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer 2019; 50 (01) 23-34